文献速递MDS 与骨髓增殖性肿瘤白血病

PHF6突变在慢性粒单核细胞白血病中界定出一个具有独特表型和更优预后的患者亚群

PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis.
PubMed 文献 · Am J Hematol · 2024-09-27

研究基于398例慢性粒单核细胞白血病(CMML)机构队列的探索性分析,发现7例PHF6突变(PHF6MUT)患者均未发生原始细胞转化;随后Mayo Clinic全院数据库检索新增28例PHF6MUT。与391例PHF6野生型(PHF6WT)相比,35例PHF6MUT更常共表达TET2、RUNX1、CBL和U2AF1突变,较少SRSF2突变,更常见Y染色体丢失和血小板<100×10^9/L。多变量分析显示PHF6MUT(HR 0.28,95%CI 0.15-0.50)和DNMT3AMUT(HR 5.8,95%CI 3.3-10.5)是最强的总生存分子预测因子。

要点

  • PHF6MUT CMML更常共表达TET2(89% vs 45%)、RUNX1(29% vs 14%)、CBL(14% vs 2%)和U2AF1(17% vs 6%)突变。
  • PHF6MUT CMML更常见Y染色体丢失(21% vs 2%)和血小板<100×10^9/L(83% vs 51%)。
  • 中位随访20个月,PHF6MUT/DNMT3AWT患者无原始细胞转化,而DNMT3AMUT和PHF6WT/DNMT3AWT患者分别有6/19(32%)和74/374(20%)发生转化。

核心结论

  • PHF6MUT界定出一个以血小板减少、Y染色体丢失率较高和预后更优为特征的CMML独特亚群。

研究设计与样本

  • 研究源于对398例CMML机构队列的探索性分析,该分析发现7例PHF6MUT患者均无原始细胞转化。
  • 随后通过Mayo Clinic全院数据库检索新增28例PHF6MUT患者。
  • 最终比较35例PHF6MUT患者与391例PHF6WT患者。

主要发现

  • PHF6MUT患者较PHF6WT更常共表达TET2突变(89% vs 45%;p<.01)、RUNX1突变(29% vs 14%;p=.03)、CBL突变(14% vs 2%;p<.01)和U2AF1突变(17% vs 6%;p=.04),较少SRSF2突变(23% vs 45%;p<.01)。
  • PHF6MUT患者更常见Y染色体丢失(21% vs 2%;p<.01)和血小板<100×10^9/L(83% vs 51%;p<.01)。
  • 多变量分析显示PHF6MUT(HR 0.28,95%CI 0.15-0.50)和DNMT3AMUT(HR 5.8,95%CI 3.3-10.5)是总生存的最强分子预测因子。
  • 无原始细胞转化生存的对应HR(95%CI)分别为PHF6MUT 0.08(0.01-0.6)和DNMT3AMUT 9.5(3.8-23.5)。
  • 中位随访20个月,33例PHF6MUT/DNMT3AWT患者中无原始细胞转化,19例DNMT3AMUT患者中6例(32%)发生转化,374例PHF6WT/DNMT3AWT患者中74例(20%)发生转化(p<.01)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The current study was inspired by observations from exploratory analyses of an institutional cohort with chronic myelomonocytic leukemia (CMML; N = 398) that revealed no instances of blast transformation in the seven patients with plant homeodomain finger protein 6 (PHF6) mutation (PHF6MUT). A subsequent Mayo Clinic enterprise-wide database search identified 28 more cases with PHF6MUT. Compared with their wild-type PHF6 counterparts (PHF6WT; N = 391), PHF6MUT cases (N = 35) were more likely to co-express TET2 (89% vs. 45%; p < .01), RUNX1 (29% vs. 14%; p = .03), CBL (14% vs. 2%; p < .01), and U2AF1 (17% vs. 6%; p = .04) and less likely SRSF2 (23% vs. 45%; p < .01) mutation. They were also more likely to display loss of Y chromosome (LoY; 21% vs. 2%; p < .01) and platelets <100 × 109/L (83% vs. 51%; p < .01). Multivariable analysis identified PHF6MUT (HR 0.28, 95% CI 0.15-0.50) and DNMT3AMUT (HR 5.8, 95% CI 3.3-10.5) as the strongest molecular predictors of overall survival. The same was true for blast transformation-free survival with corresponding HR (95% CI) of 0.08 (0.01-0.6) and 9.5 (3.8-23.5). At median 20 months follow-up, blast transformation was documented in none of the 33 patients with PHF6MUT/DNMT3AWT but in 6 (32%) of 19 with DNMT3AMUT and 74 (20%) of 374 with PHF6WT/DNMT3AWT (p < .01). The specific molecular signatures sustained their significant predictive performance in the context of the CMML-specific molecular prognostic model (CPSS-mol). PHF6MUT identifies a unique subset of patients with CMML characterized by thrombocytopenia, higher prevalence of LoY, and superior prognosis.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Tefferi A, Fathima S, Alsugair AKA, et al. PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis. Am J Hematol. 2024. PMID: 39329442. doi:10.1002/ajh.27492

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。